Voices: The University of Utah is a leading research institution. Federal changes put that at risk.
Shared investments between research institutions and the government are essential for the health, prosperity and future of ...
Daily Herald5d
Millions across the globe look to make ‘meaningful discoveries’ at 2025 RootsTech
The 15th rendition of RootsTech looks to not only cater to thousands of in-person attendees but also meet the needs of a mass ...
Myriad Genetics, Inc.: Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced a collaboration with Gabbi, a ...
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools
Gabbi’s telehealth solution provides logistics and educational support to assess breast cancer risk. Patients identified as potentially high risk are connected with a Gabbi clinician to be evaluated ...
Myriad: Q4 Earnings Snapshot
Myriad Genetics Inc. (MYGN) on Monday reported a loss of $42.5 million in its fourth quarter. The average estimate of eight analysts surveyed by Zacks Investment Research was also for earnings of 3 ...
Myriad Genetics Announces Senior Leadership Transition
Appoints Sam Raha as CEO and Mark S. Verratti as COO Effective April 30, 2025SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) - ...
The Bakersfield Californian13d
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to ...
SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a developer of artificial ...
Business Insider13d
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio
SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a developer of artificial ...
ETF Daily News14d
Myriad Genetics (NASDAQ:MYGN) Lowered to “Hold” Rating by StockNews.com
Shares of NASDAQ:MYGN opened at $14.19 on Thursday. The firm has a 50 day moving average of $13.45 and a 200-day moving average of $19.53. The stock has a market capitalization of $1.29 billion, a ...
ETF Daily News14d
Myriad Genetics (MYGN) Expected to Announce Quarterly Earnings on Tuesday
Myriad Genetics has a fifty-two week low of $12.04 and a fifty-two week high of $29.30. The company’s 50-day moving average price is $13.45 and its 200 day moving average price is $19.53.
Nasdaq14d
MYRIAD GENETICS Earnings Preview: Recent $MYGN Insider Trading, Hedge Fund Activity, and More
MYRIAD GENETICS ($MYGN) is expected to release its quarterly earnings data on Monday, February 24th after market close, per Finnhub. Analysts are expecting revenue of ...
WBUR16d
Salt unavailable to melt ice? Try some sand, molasses or pickle juice
In Chicopee, Massachusetts, a multi-day delay of 40 tons of salt based de-icer mucked up the street clean up. Several city trucks were sent earlier this week to Albany, New York, to pick up tons ...